ProCE Banner Activity

Key COVID-19 Studies Influencing My Practice Following IDWeek 2022—Audio Recap

Podcast Episodes

Listen to expert insights from Princy N. Kumar, MD, and Paul E. Sax, MD, on updates and new COVID-19 data from IDWeek 2022, including data on vaccines, risk factors and risk stratification, diagnostics, therapeutics, treatment of patients with immunocompromise, and long COVID.

Released: November 18, 2022

Share

Faculty

Princy N Kumar

Princy N Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Tropical Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Princy N Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Tropical Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP: consultant/advisor/speaker: Gilead Sciences, Johnson & Johnson, Merck, Theratechnologies, ViiV; researcher: American Gene Technologies, Gilead Sciences, GlaxoSmithKline, Merck; stock/stock options: Gilead, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer.